Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC
To evaluate the efficacy and safety of Envafolimab Plus Docetaxel in combination with or without Trilaciclib versus docetaxel IN patients with advanced non-small cell lung cancer previously treated with a PD-1 inhibitor combined with chemotherapy
Advanced Non-Small Cell Lung Cancer
DRUG: Trilaciclib+Envafolimab+Docetaxel|DRUG: Envafolimab+Docetaxel|DRUG: Docetaxel
PFS, Progression-free survival (PFS per RECIST 1.1) is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first., 12 months after the last subject participating in
ORR, The proportion of subjects with complete response (CR) and partial response (PR) in total subjects., 12 months after the last subject participating in|DCR, The proportion of subjects with complete response (CR), partial response (PR)and stable disease in(SD) in total subjects., 12 months after the last subject participating in|DoR, DoR (per RECIST 1.1) is defined as the time from the date for first documented response of complete response (CR) or partial response (PR) to the date of first documented of disease progression or death, whichever occurs first., 12 months after the last subject participating in|OS, Defined as the time from randomization to all-cause death., 24 months after the last subject participating in|QOL, Quality of life was assessed using the EQ-5D-5L scale, 24 months after the last subject participating in|The incidence of Subjects With Treatment-Emergent Adverse Events (TEAEs) According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, TEAEs will be defined as the adverse events (AEs) that occur between first dose of study drug administration and 28 days after the last dose of study drug administration, 24 months after the last subject participating in
Trilaciclib indication: Trilaciclib, a CDK4/6 inhibitor, was used before chemotherapy to reduce the incidence of bone marrow suppression, approved by FDA and NMPA for small cell lung cancer in 2021 and in 2022.

Envafolimab indication: Envafolimab, a PD-L1 inhibitor, was used for unresectable or metastatic, MSI-H or dMMR, Adult patients with advanced solid tumors, approved by NMPA in 2021.